Schering-Plough and concerns about Vytorin / Dhanishtha Kika Bhagwangar, Matthew R. Smith, James S. O'Rourke.

Format:

Book

Author/Creator:

Bhagwangar, Dhanishtha Kika, author.

Smith, Matthew R., author.

O'Rourke, James S., IV, 1946- author.

Series:

SAGE Knowledge. Cases.

SAGE Knowledge. Cases

Language:

English

Subjects (All):

Schering-Plough Corporation.

Pharmaceutical industry--Public relations.

Pharmaceutical industry.

Anticholesteremic agents--Testing.

Anticholesteremic agents.

Physical Description:

1 online resource : illustrations.

Place of Publication:

London : SAGE Publications Ltd, 2017.

System Details:

text file

Summary:

Clinical tests showed cholesterol drug Vytorin was not living up to the claims of the producers, Schering-Plough and Merck. Consumers could receive a virtually equivalent drug for one-third of the cost. The problem facing Schering-Plough was to find the best methods to reach its stakeholders and ensure them that their concerns will be addressed in a timely and effective manner. This case has health, financial, and legal ramifications for stakeholders.

Notes:

Originally published: Bhagwangar, D.K., Smith, M.R., & ORourke, J. S. (2008). Schering-Plough and concerns about Vytorin. 08-11. Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.

No ILL or scholarly sharing allowed.

Description based on XML content.

ISBN:

9781526404909

OCLC:

1017723564

Access Restriction:

Restricted for use by site license.